Illuminating immunotherapy response via precision T cell-targeted PET imaging

Area of Science:

• Oncology
• Immunology
• Nuclear Medicine

Background:

• Traditional immunotherapy strategies rely on invasive, static biopsy data, which inadequately represent the dynamic and heterogeneous tumor immune microenvironment.
• Tumor heterogeneity and distinct immune profiles across metastatic sites complicate patient selection for immunotherapy and prediction of treatment resistance.
• There is a critical need for advanced methodologies to non-invasively characterize the tumor immune microenvironment and monitor treatment response.

Purpose of the Study:

• To review T cell-targeted positron emission tomography (PET) radiopharmaceuticals for evaluating immunotherapy.
• To explore the utility of these PET agents in assessing treatment response and systemic immune activity.
• To highlight PET imaging as a non-invasive tool for understanding the tumor immune microenvironment.

Main Methods:

• Review of pre-clinical and clinical studies on T cell-targeted PET radiopharmaceuticals.
• Analysis of the application of PET imaging in evaluating immunotherapy efficacy.
• Examination of PET's role in monitoring systemic immune responses to immunotherapeutics.

Main Results:

• T cell-targeted PET radiopharmaceuticals show promise for non-invasively assessing the tumor immune microenvironment.
• PET imaging can potentially evaluate response to immunotherapy and identify resistance mechanisms.
• These agents aid in understanding the systemic immune response to immunotherapeutic treatments.

Conclusions:

• PET imaging offers a non-invasive, longitudinal approach to characterize the tumor immune microenvironment.
• T cell-targeted PET radiopharmaceuticals are valuable tools for evaluating immunotherapy response.
• This technology can improve patient selection and treatment monitoring in cancer immunotherapy.